“The concern is whether SARS-CoV-2 variants may reduce the efficacy of current vaccines that were designed to protect against the original SARS-CoV-2 strain at the beginning of the pandemic,” stated Barouch, senior creator of the research and likewise Professor of Medicine at Harvard Medical School.
‘Immune response triggered by neutralizing antibodies against the B.1.1351 and P.1 strains was less when compared to the response against the original strain.’
Barouch, Director of BIDMC’s Center for Virology and Vaccine Research, and colleagues sought to discover the immunogenicity of Ad26.COV2. S vaccine towards the unique viral pressure (WA1/2020) and variants B.1.1351, B.1.1.7, P.1, CAL.20C. They noticed about 20 volunteers between the ages of 18 and 55 who had been all individuals of a bigger multicenter, randomized, double-blind, placebo-controlled Phase 1/2a research.
Various strategies had been used to evaluate antibody and mobile immune responses.
They noticed that there have been decreased immune responses by neutralizing antibodies towards the B.1.1351 and P.1 strains in comparison with the antibody responses towards WA1/2020.
Based on the opposite outcomes from Phase 3 medical trials, the specialists hypothesized that ranges of neutralizing antibodies had been decreased towards the variants however the non-neutralizing antibodies and/or T cell responses might contribute to the safety.
“These findings, therefore, have important implications for vaccine protection against SARS-CoV-2 variants of concern,” Barouch added.